Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIANCA: Tisagenlecleucel in pediatric relapsed or refractory mature B-cell non-Hodgkin lymphoma
jRCT1080224705Phase 2Completed
- Sponsor
- Novartis
- Start
- May 2019
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
01
Overview
Phase 2, open-label, single-arm trial of tisagenlecleucel in non-Hodgkin lymphoma (NHL), Burkitt lymphoma (BL), Burkitt leukemia and 4 more, sponsored by Novartis. Primary endpoint: Overall response rate (ORR). Started May 2019; status: completed.
02
Drugs
tisagenlecleucel
03
Conditions
non-Hodgkin lymphoma (NHL)Burkitt lymphoma (BL)Burkitt leukemiadiffuse large B-cell lymphoma (DLBCL)primary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on jRCT1080224705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080224705.